Pharmacotherapy for obesity - Promise and uncertainty

New England Journal of Medicine

Volumn 353, Issue 20, 2005, Pages 2187-2189

  Yanovski, Susan Z ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; CANNABINOID RECEPTOR ANTAGONIST; DEXFENFLURAMINE; FENFLURAMINE; PHENTERMINE; RIMONABANT; SIBUTRAMINE;

BEHAVIOR THERAPY; BODY WEIGHT; CANCER; CARDIOVASCULAR RISK; DRUG WITHDRAWAL; EDITORIAL; HUMAN; LIFESTYLE; MENTAL DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRESCRIPTION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SOCIAL BEHAVIOR; TREATMENT OUTCOME; UNITED STATES; WEIGHT REDUCTION;

ANTI-OBESITY AGENTS; APPETITE DEPRESSANTS; CYCLOBUTANES; DYSLIPIDEMIAS; HUMANS; OBESITY; PIPERIDINES; PYRAZOLES; RECEPTORS, CANNABINOID; WEIGHT LOSS;

EID: 27844572849     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe058243     Document Type: Editorial

References (14)

1. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002;288:1723-7.
2. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the Evidence Report. Obes Res 1998;6:Suppl 2:51S-209S. [Erratum, Obes Res 1998;6:464.]
3. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
4. Wadden TA, Foster GD. Behavioral treatment of obesity. Med Clin North Am 2000;84:441-61.
5. Wadden TA, Berkowitz RI, Womble LG, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 2005;353:2111-20.
6. Després J-P, Golay A, Sjöström L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005;353:2121-34.
7. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005;365:1389-97. [Erratum, Lancet 2005;366:370.]
8. Colman E. Anorectics on trial: a half century of federal regulation of prescription appetite suppressants. Ann Intern Med 2005;143:380-5.
9. Weintraub M. Long-term weight control: the National Heart, Lung, and Blood Institute funded multimodal intervention study. Clin Pharmacol Ther 1992;51:581-5. [Erratum, Clin Pharmacol Ther 1992;52:323.]
10. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendations, November 1997. MMWR Morb Mortal Wkly Rep 1997;46:1061-6.
11. Blanck HM, Khan LK, Serdula MK. Prescription weight loss pill use among Americans: patterns of pill use and lessons learned from the fen-phen market withdrawal. Prev Med 2004;39:1243-8.
12. Bray GA. Uses and misuses of the new pharmacotherapy of obesity. Ann Med 1999;31:1-3.
13. Sjostrom CD. Surgery as an intervention for obesity: results from the Swedish obese subjects study. Growth Horm IGF Res 2003;13:Suppl A:S22-S26.
14. Ryan DH, Espeland MA, Foster GD, et al. Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials 2003;24:610-28.